Dr. Olalekan O. Oluwole explained how CAR T is used to treat high-risk blood cancers and highlighted the potential of outpatient CAR T-cell therapy treatment.

T-cell lymphomas occur more often in locations like Japan, China, the Caribbean, South and Central America, and West Africa, where HTLV-1 infections are more common.

In fighting chronic infections or certain cancers, CD8+ T cells—the immune system's frontline soldiers—eventually become ...

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...

"CAR-T cells attack tumors in the ovaries, but they also destroy the patient's healthy tissues, particularly the lungs. You attack the cancer, but you kill the patient," explains Prof. François.

Local immune effector cell–associated toxicity syndrome is a newly identified side effect observed in many patients receiving CD19-targeting CAR T-cell therapy for autoimmune conditions.

CAR-T cell therapy for hematologic cancers is now available at St. George Regional Hospital. Jacqueline, a Las Vegas patient who traveled to Salt Lake City for the treatment, said it saved her life.

SAN DIEGO--(BUSINESS WIRE)--Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell ...

CX-904 was the first masked T-cell engager that CytomX took into the clinic. The masking technology is designed to render the bispecific inactive until it reaches the tumor microenvironment.